MedTrace Logo

PSMA-PET/CT Registry

NCT05709535 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 128

Last updated 2024-12-18

No results posted yet for this study

Summary

This is a prospective registry study to evaluate the diagnostic utility of \[18F\]-PSMA-1007 (PSMA-PET/CT) to stage patients with high-risk prostate cancer, localize sites of biochemical recurrence of prostate cancer, and restage patients with advanced prostate cancer before onset of new therapy.

Conditions

Interventions

DIAGNOSTIC_TEST

[18F]-PSMA-1007

\[18F\]PSMA-1007 is a diagnostic radiopharmaceutical for Positron Emission Tomography (PET) scan. The intervention involves single intravenous administration of \[18F\]PSMA-1007 for PET scan.

Sponsors & Collaborators

  • AHS Cancer Control Alberta

    lead OTHER

Principal Investigators

  • Steven Yip, MD · Alberta Health services

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-11
Primary Completion
2024-11-01
Completion
2024-11-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05709535 on ClinicalTrials.gov